For hematology malignant diseases, methylation in the CpG island of ASS1 has been detected in 71.7% of multiple myeloma patients and patients with ASS1 methylation were less likely to have bone disease and extramedullary disease (43). This evidence concerns the gene ASS1 and AL amyloidosis.